Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | PARP1 | P09874 | 8/20 | 0.49 |
| ▸ | PARP6 | Q2NL67 | 7/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.49 |
| ▸ | PARP3 | Q9Y6F1 | 6/20 | 0.49 |
| ▸ | TNKS | O95271 | 4/20 | 0.49 |
| ▸ | CBFB | Q13951 | 4/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396632 | 1.00 | KDM4E (0.59) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL29396388 | 0.89 | PARP1 (0.51) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL22912723 | 0.89 | PARP1 (0.51) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL22912736 | 0.85 | KDM4E (0.59) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL29396277 | 0.85 | KDM4E (0.59) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL22912799 | 0.83 | PARP1 (0.51) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL29396728 | 0.83 | PARP1 (0.51) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL15745613 | 0.82 | CBFB (0.48) | PARP1PARP6PARP2PARP3CBFB | |
| SCHEMBL22912828 | 0.82 | PARP1 (0.52) | KDM4EPARP1PARP6PARP2PARP3 | |
| SCHEMBL22912784 | 0.82 | PARP1 (0.52) | KDM4EPARP1PARP6PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116425744-A | Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11325906-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2022-05-10 | — | — | US | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040084-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | KDM4E 544/4885PARP1 399/4885PARP6 600/4885 |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | PARP12, PARP11, PARP1 | KDM4E 2263/4885PARP1 3/4885PARP6 11/4885 |
| US-11325906-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | KDM4E 544/4885PARP1 399/4885PARP6 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.